Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Why Is Eli Lilly Investing Up to $494 Million to Study Squirrel Hibernation?
09:00am, Sunday, 31'st Dec 2023
Eli Lilly is building a foundation for a strong position in the obesity treatment market. Squirrels that hibernate are effective at both gaining and shedding weight.
Eli Lilly Stock Jumped 59% in 2023. Is It a Good Stock to Buy in 2024?
05:36am, Sunday, 31'st Dec 2023
Soaring sales of diabetes drug Mounjaro made 2023 a great year to own Eli Lilly stock. Peak annual sales of recently-approved weight-management drug Zepbound (which has the same active ingredient as M
3 Ken Griffin Stocks to Invest Like Citadel
04:00pm, Saturday, 30'th Dec 2023
Ken Griffin is the founder, CEO and majority owner of Citadel, one of the premier hedge funds. Griffin founded the company in 1990 and grew it into what it is today through a combination of quantitati
Your New Year's Resolution For 2024: Invest $10,000 In These 5 Stocks
02:54pm, Friday, 29'th Dec 2023
I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
06:48pm, Thursday, 28'th Dec 2023
The latest trading day saw Eli Lilly (LLY) settling at $580.85, representing a -0.11% change from its previous close.
Interested in the Weight-Loss Market? Here's 1 Stock to Buy Hand Over Fist in 2024, and 1 to Avoid Like the Plague.
08:30am, Thursday, 28'th Dec 2023
Eli Lilly is the developer of Mounjaro, a diabetes treatment generating billions in sales. Pfizer has had its challenges as it looks to enter the diabetes and obesity markets.
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
06:40pm, Wednesday, 27'th Dec 2023
Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
07:50am, Wednesday, 27'th Dec 2023
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic
Can This Red-Hot Stock Beat the Market Again in 2024?
04:00pm, Friday, 22'nd Dec 2023
Eli Lilly could earn an important approval in 2024. The company's financial results could improve, too.
Looking Beyond Tech: 7 High-Growth Stocks for Substantial Returns
07:51am, Friday, 22'nd Dec 2023
The tech market is surging, with a remarkable 40% year-to-date increase in the Nasdaq-100 Technology Sector. The buzz around high-growth stocks in fields including AI and cloud computing is palpable
These 3 Big Pharma Stocks Are Making Big Plays With AI
07:15am, Friday, 22'nd Dec 2023
Big drug companies want to use artificial intelligence for a handful of purposes. Finding leads to make medicines more efficiently is one in-demand application.
Eli Lilly (LLY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
06:47pm, Thursday, 21'st Dec 2023
The latest trading day saw Eli Lilly (LLY) settling at $572, representing a +0.31% change from its previous close.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
10:32am, Thursday, 21'st Dec 2023
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
09:45am, Thursday, 21'st Dec 2023
The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
11:17am, Wednesday, 20'th Dec 2023
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
